Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) indicates CimetrA has a wide-ranging application as an anti-inflammatory treatment
- Results from a study demonstrated the product could be used for more than purely the treatment of COVID-19, which had been the primary focus of clinical trials to date
- The study was undertaken by an Israeli research organisation and found CimetrA could be used for the treatment of rheumatoid arthritis, inflammatory bowel disease and asthma
- Following the study, MGC Pharma says it plans to further explore aspects of CimetrA’s profile and begin planning the next phases of its clinical development
- MGC Pharmaceuticals ends the day 5.88 per cent in the green to close at 1.8 cents
MGC Pharmaceuticals (MXC) has indicated CimetrA has a wide-ranging application as an anti-inflammatory treatment.
The company today announced an update on its pre-clinical in-vitro study for its proprietary investigation medicinal product, CimetrA.
Results from the study indicated CimetrA could be used for more than purely the treatment of symptoms of COVID-19, which had been the primary focus of clinical trials to date.
The study was undertaken by Israeli contract research organisation, Science in Action, and built on previous studies commissioned by MGC Pharma.
The study found that CimetrA moderates the body’s release of pro-inflammatory cytokines by affecting their gene expression and transcription factors.
Specifically, the study demonstrated the blocking of the pro-inflammatory cytokine related to rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis and chronic obstructive pulmonary disease.
Following the study, MGC Pharma said it plans to further explore aspects of CimetrA’s profile and begin planning the next phases of its clinical development.
Roby Zomer, Co-Founder and Managing Director of MGC Pharmaceuticals, said the announcement is a big leap forward, with more conditions potentially being treatable with the drug.
“Its anti-inflammatory profile means that it could transform the lives of thousands of patients, and it is particularly reassuring that these latest results confirm the findings of previous studies,” he said.
“In light of these results, MGC is in the process of designing the next phase of CimetrA’s clinical pathway and will keep everyone updated.”
MGC Pharmaceuticals has ended the day 5.88 per cent in the green to close at 1.8 cents.
